Sagimet Biosciences Inc.
SGMT
$5.14
-$0.07-1.34%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.31% | 8.35% | 9.38% | 29.01% | 4.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -40.84% | -15.19% | 12.62% | 126.56% | 92.21% |
| Operating Income | 40.84% | 15.19% | -12.62% | -126.56% | -92.21% |
| Income Before Tax | 40.94% | 11.70% | -27.94% | -174.19% | -98.76% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 40.94% | 11.70% | -27.94% | -174.19% | -98.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 40.94% | 11.70% | -27.94% | -174.19% | -98.76% |
| EBIT | 40.84% | 15.19% | -12.62% | -126.56% | -92.21% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 41.53% | 12.58% | -26.81% | -147.31% | -44.76% |
| Normalized Basic EPS | 41.53% | 12.59% | -26.79% | -147.23% | -44.73% |
| EPS Diluted | 41.53% | 12.58% | -26.81% | -147.31% | -44.76% |
| Normalized Diluted EPS | 41.53% | 12.59% | -26.79% | -147.23% | -44.73% |
| Average Basic Shares Outstanding | 1.01% | 1.00% | 0.88% | 10.87% | 37.31% |
| Average Diluted Shares Outstanding | 1.01% | 1.00% | 0.88% | 10.87% | 37.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |